A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.

This study has been terminated.
Information provided by:
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
First received: May 23, 2007
Last updated: March 19, 2008
Last verified: March 2008
This single arm study will assess the efficacy of loading doses of intravenous Bondronat in reducing pain in patients with breast cancer and metastatic bone disease experiencing moderate to severe bone pain. Patients will receive an intravenous infusion of 6mg Bondronat on days 1, 2 and 3. The anticipated time on study treatment is <3 months, and the target sample size is <100 individuals.

Condition Intervention Phase
Bone Neoplasms;
Neoplasm Metastasis
Drug: ibandronate [Bondronat]
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Study to Assess the Effect of Intravenous Loading Doses of Bondronat on Metastatic Bone Pain in Patients With Breast Cancer and Skeletal Metastases.

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Pain response (20% decrease in mean pain score compared to baseline, and <=50% increase in mean analgesic consumption [ Time Frame: Days 5 - 7 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Mean worst pain score over first 7 days [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • Analgesic consumption [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • Karnofsky index [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • AEs, laboratory parameters [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 52
Estimated Study Completion Date: January 2008
Arms Assigned Interventions
Experimental: 1 Drug: ibandronate [Bondronat]
6mg iv on days 1-3


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients, >=18 years of age;
  • breast cancer;
  • bone metastases;
  • mean worst pain score >=4 during 3 day baseline period;
  • stable dose of analgesics over a 3 day baseline period;
  • adequate renal function.

Exclusion Criteria:

  • bisphosphonate treatment within 3 weeks of study enrollment;
  • a change in antineoplastic treatment within 6 weeks of study enrollment;
  • bone radiation within 2 weeks of study enrollment;
  • active infection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00478270

Alexandroupolis, Greece
Athens, Greece
Haidari, Greece
Patras, Greece
Piraeus, Greece
Thessaloniki, Greece
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Clinical Trials, Study Director, Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00478270     History of Changes
Other Study ID Numbers: ML20247 
Study First Received: May 23, 2007
Last Updated: March 19, 2008
Health Authority: Greece: E.O.F. (National drug organization)

Additional relevant MeSH terms:
Bone Neoplasms
Neoplasm Metastasis
Bone Diseases
Musculoskeletal Diseases
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Ibandronic acid
Bone Density Conservation Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 26, 2016